TriSalus Life Sciences Q2 revenue beats estimates
TLSI•Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
- The average consensus recommendation for the biotechnology & medical research peer group is "buy".
- Wall Street's median 12-month price target for TriSalus Life Sciences Inc is $9.00, about 94.8% above its August 5 closing price of $4.62.
Outlook and result drivers
- TriSalus maintains 2026 revenue guidance of $54 million to $57 million.
- Company expects further growth in the second half of 2026 and beyond.
- Sales and marketing expenses - Operating losses increased mainly due to higher sales and marketing costs from expanding the sales organization.
- Gross margin improvement - Gross margin rose to 86.8% from 83.9% a year earlier, mainly due to lower cost per TriNav unit.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $11.41 million | $10.27 million (4 Analysts) |
| Q2 Gross Profit | $9.90 million | ||
| Q2 Income from Operations | -$9.81 million | ||
| Q2 Pretax Loss | $9.18 million |
